コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nhibit RNA topoisomerase activity of E. coli DNA topoisomerase I.
2 camptothecin sensitivity of yeast and human DNA topoisomerase I.
3 -kDa N-terminal fragment of Escherichia coli DNA topoisomerase I.
4 t of the known structures of yeast and human DNA topoisomerase I.
5 nd unwinds DNA in the presence of eukaryotic DNA topoisomerase I.
6 chain and amino acids of the active site of DNA topoisomerase I.
7 shown previously to act as poisons of human DNA topoisomerase I.
8 ding of the modified DNA substrates by human DNA topoisomerase I.
9 mplate and DNA synthesis absolutely required DNA topoisomerase I.
10 upercoiled in Escherichia coli cells lacking DNA topoisomerase I.
11 found to have 100% sequence homologies with DNA topoisomerase I.
12 does not result from elevated expression of DNA topoisomerase I.
13 on of DNA damage induced by camptothecin and DNA topoisomerase I.
14 aining a deletion of topA (the gene encoding DNA topoisomerase I) a compensatory mutation is found in
15 substitution mutagenesis of Escherichia coli DNA topoisomerase I, a member of the type IA subfamily o
16 eplisomes with camptothecin (CPT)-stabilized DNA-Topoisomerase I adducts activates an ATR-dependent p
17 Therapy for ERMS included alkylating agents, DNA topoisomerase I and DNA topoisomerase II inhibitors,
21 thin the other component are factors, namely DNA topoisomerase I and PC4, previously shown to serve a
22 the nuclear mitotic apparatus protein NuMA, DNA topoisomerases I and II, and the RNA polymerase I up
23 results, E. coli cells lacking both type IA DNA topoisomerases I and III are found to be nonviable,
24 urther confirmed to be DNA polymerase alpha, DNA topoisomerase I, and PCNA by immunoprecipitation exp
26 RNP, anti-SSA/Ro, anti-SSB/La, anti-Scl-70 (DNA topoisomerase I), anticentromere, and anti-Jo-1 anti
27 the active site tyrosine of Escherichia coli DNA topoisomerase I are conserved among the type IA topo
28 11, Asp-113, and Glu-115 of Escherichia coli DNA topoisomerase I are located near the active site Tyr
30 DNA from the 5' side of a nick generated by DNA topoisomerase I at a ribonucleoside monophosphate re
31 hput assay to screen for inhibitors of human DNA topoisomerase I based on the scintillation proximity
34 -b]pyran-5,6-dione (beta-lapachone) inhibits DNA topoisomerase I by a mechanism distinct from that of
35 The antitumor agent camptothecin targets DNA topoisomerase I by reversibly stabilizing a covalent
36 l result in severely compromised enzymes and DNA topoisomerase I-camptothecin dependent lethality.
39 a new class of anticancer drugs that target DNA topoisomerase I; current efforts are directed toward
43 xtraction, regions of the DNA polymerase and DNA topoisomerase I genes were amplified by PCR, sequenc
44 logical probe, we find that Escherichia coli DNA topoisomerase I has low RNA topoisomerase activity a
46 e response represents a new role for E. coli DNA topoisomerase I in addition to prevention of excessi
47 icting results regarding the essentiality of DNA topoisomerase I in cells grown in media of low osmol
49 ults thus implicate an indispensable role of DNA topoisomerase I in E. coli cells grown in media of a
50 the rDNA and clarifies a structural role of DNA topoisomerase I in the epigenetic regulation of rDNA
52 Mutations in two conserved regions of yeast DNA topoisomerase I induced a similar mechanism of cell
53 lkynyl side chains display excellent E. coli DNA topoisomerase I inhibition properties with IC50 valu
54 been synthesized and their Escherichia coli DNA topoisomerase I inhibition, binding to B-DNA duplex,
55 The anticancer agent camptothecin (CPT) is a DNA topoisomerase I inhibitor that causes fork collapse
56 sphorylated within 1 h after addition of the DNA topoisomerase I inhibitor, camptothecin, and that la
60 matography and overlay blotting that E. coli DNA topoisomerase I interacts directly with the RNA poly
63 raction between camptothecin derivatives and DNA topoisomerase I is essential in the induction of rad
68 stidine residue, His-365 in Escherichia coli DNA topoisomerase I, is located at the active site of ty
70 lts suggest distinct mechanisms of poisoning DNA topoisomerase I may be explored in the development o
71 mechanisms underlying cellular responses to DNA topoisomerase I-mediated DNA damage are conserved be
73 t study, we investigated the role of Ku86 in DNA topoisomerase I-mediated radiosensitization induced
74 with enhanced sensitivity to self-poisoning DNA topoisomerase I mutant (Top1T722Ap), which mimics th
75 ture-sensitive growth in the presence of the DNA topoisomerase I mutant, Top1T722Ap, were selected.
76 to the cytotoxic activity of Cpt or specific DNA topoisomerase I mutants, we initiated a genetic scre
78 patients with SSc who are positive for anti-DNA topoisomerase I or anticentromere autoantibodies.
79 SSc patients who had either circulating anti-DNA topoisomerase I (P=7.58x10(-17)/4.84x10(-16)) or ant
82 inus of this alpha helix in Escherichia coli DNA topoisomerase I showed that flexibility around this
83 gs1 top1 double mutant lacking both Sgs1 and DNA topoisomerase I showed that the slow growth phenotyp
84 a protein homologous to the Escherichia coli DNA topoisomerase I subfamily of enzymes has been identi
85 rity, results from the synthesis of a mutant DNA topoisomerase I that is itself temperature-sensitive
92 n (CPT) and its derivatives target mammalian DNA topoisomerase I (top1) and are among the most effect
95 s such as DNA replication and transcription, DNA topoisomerase I (Top1) catalyzes the relaxation of D
100 il (FU), is most closely correlated with the DNA topoisomerase I (Top1) inhibitor camptothecin in the
101 modified DNA lesions have been shown to trap DNA topoisomerase I (TOP1) into covalent cleavage comple
102 s containing wild-type and mutant alleles of DNA topoisomerase I (TOP1) into the haploid yeast gene-d
110 reated with camptothecin (CPT), a eukaryotic DNA topoisomerase I (TOP1) poison which induces TOP1-med
111 e show rapid recruitment, within minutes, of DNA topoisomerase I (TOP1) to a large cohort of AR-regul
112 uracil mismatches, nicks, and gaps can trap DNA topoisomerase I (top1) when these lesions are introd
124 tokines in regulating the production of anti-DNA topoisomerase I (topo I) Ab, a major autoantibody in
125 xyl-terminal amino acids of Escherichia coli DNA topoisomerase I (Topo I) and III (Topo III) play in
132 hydrophilic N-terminal domain of eukaryotic DNA topoisomerase I (topo I) is dispensable for catalyti
136 f the deduced amino acid sequence with other DNA topoisomerase I (topo I) protein sequences shows a s
138 luding DNA polymerase alpha (DNA pol alpha), DNA topoisomerase I (topo I), and proliferating-cell nuc
139 responses to various autoantigens, including DNA topoisomerase I (Topo I), have been implicated.
142 inding DNA ligands that uses closed circular DNA, topoisomerase I (Topo I), and two-dimensional agaro
143 tigens and also revealed increased levels of DNA topoisomerase I transcripts in SSc fibroblasts compa
145 The viability of the topA mutants lacking DNA topoisomerase I was thought to depend on the presenc
146 merase and the C-terminal domains of E. coli DNA topoisomerase I, which are homologous to the zinc ri
147 AA-etherA inhibition of DNA replication are DNA topoisomerase I, which is inhibited by AA-etherA in
149 n yeast (delta)top1 cells lacking endogenous DNA topoisomerase I yielded an activity in cell extracts
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。